PVX-108 for Peanut Allergy
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you have severe or unstable asthma, or are on certain asthma treatments, you may not be eligible to participate.
What safety data exists for PVX-108 or similar treatments for peanut allergy?
What is the purpose of this trial?
The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
Research Team
Brian Vickery, MD
Principal Investigator
Emory University
Eligibility Criteria
This trial is for children and adolescents with a doctor-confirmed peanut allergy, demonstrated by specific blood tests and skin prick tests. They must have had a reaction to a small amount of peanut protein in a controlled test. Kids with moderate or severe asthma are excluded, as well as those who've tried desensitizing treatments before.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive twelve 4-weekly intradermal doses of PVX108 or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- PVX-108
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aravax Pty Ltd
Lead Sponsor